Compare Dolby Laboratories, Inc. (DLB) vs Medtronic PLC (MDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dolby Laboratories, Inc. vs Medtronic PLC — how do they compare? Dolby Laboratories, Inc. trades at $58.74 (market cap $5.47B), while Medtronic PLC trades at $88.48 (market cap $112.24B). The key difference: Medtronic PLC is far larger — about 20.5× Dolby Laboratories, Inc.'s market cap, and Medtronic PLC pays the higher dividend (3.28%). Which is the better fit depends on your goals — on Pluang, investors hold Dolby Laboratories, Inc. for 98 Days and Medtronic PLC for 63 Days on average.
| DLB | MDT | |
|---|---|---|
Market Cap | $5.47B | $112.24B |
Volume | 1,058,284 | 105,663,236 |
Sector | Technology | Health |
52-Week High | $69.58 | $105.35 |
52-Week Low | $48.51 | $73.75 |
Typical Hold Time | 98 Days | 63 Days |
Enterprise Value | $4.85B | $131.58B |
Dividend Yield | 2.46% | 3.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dolby Laboratories (DLB) trades at $58.45, showing modest daily gains of 0.17%. The stock faces bearish technical signals with resistance at $59 and support at $58. Fundamentally, DLB maintains strong profitability with 87.61% gross margins and has beaten earnings estimates in three consecutive quarters. Recent developments include expanded partnerships with Meta and leadership transition to new CEO Marc Whitten.
DLB presents a mixed outlook with analyst consensus pointing to significant upside (target $90.33) despite near-term execution risks. The company's strong cash position and expanding digital content partnerships provide growth catalysts, though licensing volatility and competitive pressures remain key challenges for investors.
Medtronic (MDT) trades at $87.75, up 2.62% today, with strong fundamental performance including three consecutive quarterly earnings beats and a 49-year dividend growth streak. The stock shows bearish technical signals but maintains solid profitability with 13.93% net margins and positive cash flow trends. Recent regulatory approvals for medical devices and raised guidance signal operational momentum despite mixed technical indicators.
Outlook remains positive with analyst consensus at $97.80 (11% upside) and no sell ratings, though technical weakness and increasing debt-to-asset ratios pose near-term risks. The 3.2% dividend yield provides income support while revenue growth acceleration to $37.5B projected for 2026 offers growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
